Combining the evaluation of PD‐L1 and major histocompatibility complex (MHC) class I, also known as HLA‐I, has been proposed as a potential biomarker for PD‐1/PD‐L1 inhibitor response in BC [21]. The gene discussed is PDCD1; the disease is breast cancer.